Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta.

Marchington, D; Malik, S; Banerjee, A; Turner, K; Samuels, D; Macaulay, V; Oakeshott, P; Fratter, C; Kennedy, S; Poulton, J

Journal article

Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta.

Abstract:: BACKGROUND: Families with a child who died of severe, maternally inherited mitochondrial DNA (mtDNA) disease need information on recurrence risk. Estimating this risk is difficult because of (a) heteroplasmy-the coexistence of mutant and normal mtDNA in the same person-and (b) the so-called mitochondrial bottleneck, whereby the small number of mtDNAs that become the founders for the offspring cause variation in dose of mutant mtDNA. The timing of the bottleneck and of segregation of mtDNA during foetal life determines the management options. Therefore, mtDNA heteroplasmy was studied in oocytes and placenta of women in affected families. RESULTS: One mother of a child dying from Leigh syndrome due to the 9176T-->C mtDNA mutation transmitted various loads of mutant mtDNA to < or =3 of 20 oocytes. This was used to estimate recurrence as < or =5%. She subsequently conceived a healthy son naturally. Analysis of the placenta showed that some segregation also occurred during placental development, with the mutant mtDNA load varying by >10% in a placenta carrying 65% 3243A-->G mutant mtDNA. DISCUSSION: This is the first report of (a) an oocyte analysis for preconception counselling, specifically, refining recurrence risks of rare mutations and (b) a widely different load of a pathogenic mtDNA mutation in multiple oocytes, apparently confined to the germline, in an asymptomatic carrier of an mtDNA disease. This suggests that a major component of the bottleneck occurs during oogenesis, probably early in the foetal life of the mother. The variable mutant load in placenta implies that estimates based on a single sample in prenatal diagnosis of mtDNA disorders have limited accuracy.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Marchington, D., Malik, S., Banerjee, A., Turner, K., Samuels, D., Macaulay, V., Oakeshott, P., Fratter, C., Kennedy, S., & Poulton, J. (2010). Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta. Journal of Medical Genetics, 47(4), 257–261.

MLA Style

Marchington, D., et al. “Information for Genetic Management of MtDNA Disease: Sampling Pathogenic MtDNA Mutants in the Human Germline and in Placenta.” Journal of Medical Genetics, vol. 47, no. 4, 2010, pp. 257–61.

Chicago Style

Marchington, D, S Malik, A Banerjee, K Turner, D Samuels, V Macaulay, P Oakeshott, C Fratter, S Kennedy, and J Poulton. 2010. “Information for Genetic Management of MtDNA Disease: Sampling Pathogenic MtDNA Mutants in the Human Germline and in Placenta.” Journal of Medical Genetics 47 (4): 257–61.
Share
Print